Patent Daily RSS
Twitter Guna
- Access the Bayer’s appeal - bit.ly/Lj9RMP 6 days ago
- Bayer seeks to stay the operation of the CL order - bit.ly/JBAlIS 6 days ago
- USPTO Offers Patent Applicants Option to Supplement Disclosure of Prior Art After Paying Issue Fee - bit.ly/Ju5BYd 1 week ago
- Piramal Healthcare to buy US firm to boost R&D - bit.ly/MiVA1V 1 week ago
- Financial challenges, novel drug devpt pressures to hamper India’s R&D growth: Expert - bit.ly/JHsWnw 1 week ago
- Biotech body criticises Bayer on cancer drug - bit.ly/J5DEpF 1 week ago
- India drugs inquiry could prompt new U.S. scrutiny - reut.rs/JDVT5y 1 week ago
- Cipla breached patent rights by slashing cancer drug price: Bayer - bit.ly/JyCBys 2 weeks ago
- No pharma application pending for compulsory licence: Govt - bit.ly/K3OUQy 2 weeks ago
- India’s patent protection regime to be key issue in talks with US - bit.ly/Jfhluh 2 weeks ago
Daily Archives: 15/06/2011
EPO revokes Esomeprazole patent
[WSJ] [Bloomberg] [Pharmaletter] EPO last Friday revokes EP1020461, which covers magnesium salt of Esomeprazole and it is divisional patent of EP0652872 (product patent). ’461 patent revocation status not yet updated in European patent register. ’461 patent was opposed by many companies including Teva, Hexal, Lupin etc. … Continue reading